A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRANSFORM-UK
- 29 Nov 2017 Planned End Date changed from 30 Sep 2017 to 30 Mar 2018.
- 29 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
- 10 Jun 2017 Biomarkers information updated